<DOC>
	<DOCNO>NCT01048671</DOCNO>
	<brief_summary>To evaluate management HIV-1 participant treat antiretroviral combination therapy include integrase inhibitor raltegravir , across country France .</brief_summary>
	<brief_title>Management Human Immunodeficiency Virus 1 ( HIV-1 ) Participants Treated With Antiretroviral ( ARV ) Combination Therapy Including Raltegravir ( MK-0518-138 )</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Integrase Inhibitors</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<mesh_term>HIV Integrase Inhibitors</mesh_term>
	<criteria>Participant Infected With HIV1 . Participant raltegravir therapy decide start less 30 day prior inclusion study . Participant receive oral write information study agree computer processing his/her personal data . Participant take part clinical trial ass raltegravir . Participant raltegravir treatment start 30 day ago .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>HIV</keyword>
</DOC>